HealthMore in Health→
New GLP-3 Agonist Retatrutide Slashes Weight and Blood Sugar in Phase III Trial
Key Takeaways
- Retatrutide is a GLP-3 agonist targeting GIP, GLP-1, and glucagon receptors.
- Phase III trial enrolled 537 adults with type 2 diabetes across 48 sites.
- Nearly 90% achieved HbA1c below 7%; up to 40% reached normal levels.
- Participants lost 11.5% to 15.3% body weight vs. 2.6% with placebo.
DE
DT Editorial Team··via medicalxpress.com
